FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
The news came shortly after the company reported quarterly earnings that investors found lackluster.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.